Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
Status:
Completed
Trial end date:
2020-11-18
Target enrollment:
Participant gender:
Summary
The primary efficacy objective of the study is to determine if adjunctive therapy of
natalizumab 300 mg intravenous (IV) every 4 weeks reduces the frequency of seizures in adult
participants with drug-resistant focal epilepsy. The secondary efficacy objective is to
assess the effects of natalizumab versus placebo in drug-resistant focal epilepsy on
additional measures of seizure frequency.